BSC2200

BSC2200 is a preclinical-stage small molecule developed by BiSiChem that targets the Transforming Growth Factor-beta (TGF-β) signaling pathway. It is designed to function both as a standalone therapeutic and as a payload for antibody-drug conjugates (ADCs). TGF-β is a pleiotropic cytokine involved in various physiological and pathological processes, including cell proliferation, differentiation, and immune regulation. In the context of oncology, TGF-β signaling often promotes tumor progression, epithelial-mesenchymal transition (EMT), and immunosuppression within the tumor microenvironment. By inhibiting TGF-β, BSC2200 aims to counteract these pro-tumorigenic effects and enhance the efficacy of cancer treatments.